Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.35 |
| ▸ | QPCT | Q16769 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3916349 | 0.88 | PDPK1 (0.40) | — | |
| SCHEMBL3911396 | 0.84 | TP53 (0.53) | LMNAHTTCYP11B1CYP11B2CYP19A1 | |
| SCHEMBL3921773 | 0.80 | SMN1; SMN2 (0.50) | LMNAHTTSCDCYP11B1CYP11B2 | |
| SCHEMBL3111412 | 0.79 | CYP11B1 (0.51) | LMNAHTTCYP11B1CYP11B2CYP19A1 | |
| SCHEMBL3914923 | 0.78 | CYP11B1 (0.54) | LMNAHTTCYP11B1CYP11B2CYP19A1 | |
| SCHEMBL3912721 | 0.77 | CYP11B1 (0.54) | LMNACYP11B1CYP11B2IDO1 | |
| SCHEMBL2400441 | 0.77 | CYP11B2 (0.56) | LMNANPBWR1CYP11B1CYP11B2IDO1 | |
| SCHEMBL3913086 | 0.77 | ABCC8 (0.49) | HTTCYP11B1CYP11B2CYP19A1MEN1 | |
| SCHEMBL3914606 | 0.77 | GRM2 (0.44) | LMNAHTTSCDCYP11B1CYP11B2 | |
| SCHEMBL3921634 | 0.76 | EGLN1 (0.53) | LMNAHTTCYP11B1CYP11B2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | TK1, ABL1, ROR1 | LMNA 1139/4885HTT 3456/4885NPBWR1 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.